炎症性肠病患者中COVID-19的流行病学及治疗对结局的影响
该文综述炎症性肠病患者COVID-19的患病率与临床结局。患者中COVID-19患病率与普通人群相当,抗肿瘤坏死因子-α治疗与更好的临床结局相关,消化科医生提供的管理与治疗有效降低COVID-19风险。
要点
- 炎症性肠病患者COVID-19患病率与普通人群相当。
- 抗肿瘤坏死因子-α治疗似乎可减轻COVID-19病程。
- 消化科医生提供的管理与治疗有效降低COVID-19风险。
核心结论
- 炎症性肠病患者COVID-19患病率与普通人群相当,抗肿瘤坏死因子-α治疗似乎可减轻COVID-19病程。
研究设计与样本
- 综述炎症性肠病患者COVID-19患病率与临床结局的数据。
主要发现
- 炎症性肠病患者COVID-19患病率与普通人群相当。
- 使用抗肿瘤坏死因子-α药物的治疗与更好的临床结局相关。
临床怎么用
- 消化科医生提供的管理与治疗在降低COVID-19风险方面有效。
- 抗肿瘤坏死因子-α药物似乎可减轻COVID-19病程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome. METHODS: We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD. RESULTS: COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-α agents have been associated with better clinical outcomes. DISCUSSION: Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-α agents seem to mitigate the course of COVID-19.
引用
- Papa A, Gasbarrini A, Tursi A, et al. Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2020. PMID: 32826572. doi:10.14309/ajg.0000000000000830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。